Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2000
Business Overview: The Company operates in two segments: Animal Health Products and Research & Development (R&D). Primary customers are in the U.S. dairy and beef industries. Key products include FIRST DEFENSE, KAMAR HEATMOUNT DETECTOR, and WIPE OUT DAIRY WIPES.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 2000 | 9 Months Ended Sep 30, 2000 |
|---|---|---|
| Total Revenues | $1,137,584 | $4,043,489 |
| Net Profit (Loss) | $(13,483) | $277,965 |
| Operating Income (Loss) | $(30,265) | $232,987 |
| Gross Margin (Product Sales) | 47% | 50% |
| Cash and Equivalents | $1,940,531 | $1,940,531 (Ending Balance) |
| Net Cash from Operations | N/A | $(124,280) |
| Total Debt (Current + Long Term) | $439,535 | $439,535 |
| Working Capital | $2,834,320 | $2,834,320 |
Material Changes vs. Prior Period
- Revenue: Total revenues decreased 2% ($22,000) in the quarter compared to the prior year but increased 12% ($438,000) for the nine-month period.
- Profitability: The Company reported a net loss of $13,483 for the quarter, compared to a net profit of $63,188 in the same period in 1999. For the nine months, net profit was $277,965, down from $396,069 in 1999.
- Product Sales: Quarterly product sales declined 4% due to a backlog of FIRST DEFENSE orders valued at approximately $380,000. Nine-month product sales increased 13%.
- Gross Margin: Gross margin percentage decreased from 53% to 47% in the quarter and from 55% to 50% for the nine months, primarily due to the lower margin profile of the new WIPE OUT product.
- Expenses: R&D expenses increased 23% in the quarter and 18% for the nine months. Sales and marketing expenses increased 16% in the quarter and 18% for the nine months.
- Liquidity: Cash and cash equivalents increased by $117,000 during the nine-month period, driven by $318,372 in proceeds from stock option exercises, offset by negative operating cash flow.
Outlook, Risks, and Management Commentary
- Order Backlog: Management anticipates a backlog of approximately $600,000 for FIRST DEFENSE as of November 3, 2000, which may not be fully filled before year-end.
- Capital Expenditures: The Company is undertaking a $600,000 facility expansion and investing $200,000 in manufacturing equipment to increase capacity for FIRST DEFENSE and bring WIPE OUT assembly in-house. Completion is expected in Q2 2001.
- R&D Focus: R&D spending is focused on animal health products, including a new mastitis treatment using Nisin and a water pathogen detection product. The Company has reduced investment in human health programs.
- Licensing: In September 2000, the Company extended its license for the KAMAR HEATMOUNT DETECTOR through 2004, agreeing to higher royalties in exchange for reduced marketing funding obligations.
- Risks: Forward-looking statements are subject to risks regarding regulatory approvals, product development delays, and market competition. TIP-TEST sales remain limited by state regulatory barriers.
Investor Verification Checklist
- Verify the ability to fulfill the $600,000 FIRST DEFENSE order backlog before year-end.
- Monitor the impact of the new WIPE OUT product on overall gross margins.
- Assess the timeline and cost overruns for the $800,000 in planned capital expenditures (facility and equipment).
- Review progress on regulatory approvals for TIP-TEST and new Nisin-based products.
- Confirm the status of the search for a partner to fund the DIFFGAM clinical development program, as the previous grant funding has been exhausted.